Himalaya Nutravedics India

Himalaya Nutravedics India

LISTED

IPO Date: 22 Sept - 24 Sept 2026

Listing Date: 29 Sept 2026

Price Range

Rs.100 - Rs.106

Issue Size

27 Cr

Min Investment

₹2,40,000

2 lots minimum (SEBI rule for SME)

Min Application

2400 Shares

1200 per lot × 2

Schedule of Himalaya Nutravedics India

  1. Issue open date

    22 Sept 2026

  2. Issue close date

    24 Sept 2026

  3. UPI mandate deadline

    24 Sept 2026 (5 PM)

  4. Allotment finalization

    25 Sept 2026

  5. Share credit

    28 Sept 2026

  6. Listing date

    29 Sept 2026

  7. Mandate end date

    9 Oct 2026

Issue size

Funds Raised in the IPOAmount
Overall27 Cr
Fresh Issue26.5 Cr
Offer for Sale0 Cr

Allotment DetailsNew

Allotment TimelineDetails
Allotment Date25 Sept 2026
Allotment Link{Link}

Grey Market Premium

New

Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.

DateIPO PriceGMPEst. Listing Price
29 Sept 2026Latest₹106₹0₹106(0%)
28 Sept 2026₹106₹0₹106(0%)
27 Sept 2026₹106₹0₹106(0%)
26 Sept 2026₹106₹0₹106(0%)
25 Sept 2026₹106₹0₹106(0%)
24 Sept 2026₹106₹0₹106(0%)
23 Sept 2026₹106₹0₹106(0%)
22 Sept 2026₹106₹0₹106(0%)
21 Sept 2026₹106₹0₹106(0%)
20 Sept 2026₹106₹0₹106(0%)
19 Sept 2026₹106₹0₹106(0%)
18 Sept 2026₹106₹0₹106(0%)

Performance Himalaya Nutravedics India

Issue PriceListing GainCurrent Market PriceP/L
Rs.100 - Rs.106₹ 118 (11.32%) ₹ 11710.38%

About Himalaya Nutravedics India

Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. Its product portfolio includes classical Ayurvedic formulations based on recognised Ayurvedic texts, proprietary Ayurvedic formulations and nutraceutical supplements. The products are available in dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. Its nutraceutical products include formulations using vitamins, minerals, herbal extracts, amino acids and other permitted ingredients. The company operates through both its own-brand and third-party manufacturing businesses. It commenced manufacturing operations in September 2022 from its facility in Cherlapally, Hyderabad, Telangana. The company has a stockist-driven distribution network across multiple states in India and an on-ground sales and marketing team of approximately 56 personnel, including regional managers and medical representatives. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Funding capital expenditure requirements — Rs 13.75 crore Investment in branding, digital marketing, and sales expansion — Rs 7.50 crore General corporate purposes.

Founded in2022
Managing directorMr Rohit Asawa
Parent organization

Financial Overview

Strengths

5
  1. 1

    Integrated manufacturing facility capable of producing multiple dosage forms.

  2. 2

    Diverse Ayurvedic and nutraceutical product portfolio across key therapeutic areas.

  3. 3

    Established B2B distribution network with presence across 17 Indian states.

  4. 4

    Track record of strong revenue and net profit growth over recent fiscal years.

  5. 5

    In-house quality assurance and control capabilities across production processes.

Risks

5
  1. 1

    High revenue reliance on Ayurvedic products, accounting for over 90% of sales.

  2. 2

    Significant revenue concentration from top 10 customers representing over 80% of revenue.

  3. 3

    Operations from a single leased manufacturing facility located in Hyderabad, Telangana.

  4. 4

    Pending trademark opposition proceedings for corporate logos and mark applications.

  5. 5

    History of negative cash flows from operating activities due to working capital needs.

Subscription Figures

CategorySubscription (No. of times)
Qualified Institutional Buyers (QIBs)N/A
Non-Institutional Investors (NIIs)0.14
Retail Individual Investors (RIIs)0.16
EmployeeN/A
Total0.11